Check and block early liver spread in colon or rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 study tests whether giving a “blocking” treatment can prevent early liver metastasis in people with colon or rectal cancer. It uses a blood test to find circulating tumor cells before they reach the liver and aims to stop cancer from spreading.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18–80 years old
- You have confirmed colon or rectal adenocarcinoma (cancer of the gland type)
- You already had curative (radical) surgery for your cancer
- Scans show no liver metastasis (and no metastasis to other organs)
- A blood test found at least 1 tumor cell before the liver (pre-hepatic CTC)
- You are well enough for study activity (ECOG 0–1) and can attend visits and tests
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests a treatment approach for colorectal cancer that cannot be removed with surgery at first but has spread only to the liver. It is intended for people whose tumor is RAS/BRAF “wild-type” and who are well enough to do daily activities, to see if the treatment can control the cancer better.
This study looks for early signs that treatment is not working in people with stage IV colon or rectal cancer that has spread only to the liver. It may help doctors adjust care sooner by using regular blood, stool, and tissue samples around liver procedures.
This trial tests whether adding an EGFR-targeting antibody to chemotherapy can help people with colorectal cancer that has spread to the liver. It's for those whose tumors have a normal RAS gene and who have not had treatment before.
This Phase 3 trial tests whether an added “maintenance” treatment after liver surgery can help prevent colorectal cancer from coming back. It is only for people whose blood test (ctDNA) still shows signs of cancer after their operation.
This Phase 3 trial tests different ways to deliver chemotherapy for colon cancer that has spread only to the liver (with limited possible tiny lung spots). It looks at whether the treatment plan improves outcomes compared with another chemotherapy approach, using oxaliplatin and LV5FU2 (with or without irinotecan) plus an added targeted medicine.
This trial is testing a new way to give the chemotherapy drug paclitaxel directly into the liver (through a tiny tube) along with standard systemic treatment for people whose colorectal cancer has spread only to the liver and cannot be surgically removed. The goal is to see if this targeted approach works better than standard treatment alone.
Hear when a new Preventive Effect of Quintuple Therapy on Metachronous Liver Metastases in Patients With Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.